Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides

BACKGROUND: CRISPR-Cas9 has been developed as a therapeutic agent for various infectious and genetic diseases. In many clinically relevant applications, constitutively active CRISPR-Cas9 is delivered into human cells without a temporal control system. Excessive and prolonged expression of CRISPR-Cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yan-ru, Wang, Shao-jie, Chen, Jun, Li, Jie, Chen, Wenzhang, Wang, Shuyue, Meng, Bing, Zhu, Wei, Zhang, Zhuhong, Yang, Bei, Jiang, Biao, Yang, Guang, Ma, Peixiang, Liu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045643/
https://www.ncbi.nlm.nih.gov/pubmed/32102684
http://dx.doi.org/10.1186/s13059-020-01956-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045643/
https://www.ncbi.nlm.nih.gov/pubmed/32102684
http://dx.doi.org/10.1186/s13059-020-01956-x

Ejemplares similares